Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902627 | 0.88 | MERTK (0.58) | MAPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10422388 | 0.81 | TSHR (0.50) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL2896050 | 0.81 | MERTK (0.58) | MAPK1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL2898995 | 0.79 | MERTK (0.59) | MAPK1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL2902504 | 0.77 | MERTK (0.56) | MAPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2904234 | 0.73 | MERTK (0.68) | MAPK1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL16969423 | 0.73 | MERTK (0.51) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2902213 | 0.72 | KMT2A (0.43) | MAPK1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL28054673 | 0.72 | TSHR (0.49) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2902625 | 0.71 | MERTK (0.52) | MAPK1MAPTLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | claimed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | claimed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | claimed |
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | disclosed |
| US-8309602-B2 | Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | disclosed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | PNP, POLRMT, QTRT1 | MAPK1 1467/4885MAPT 1372/4885LMNA 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.